Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.
OBJECTIVE
High prevalence of metabolic syndrome (MS) and related metabolic disturbances in patients with schizophrenia and bipolar affective disorder have been in main focus of interest in recent years since the introduction of second-generation antipsychotics. This study aims to examine these questions: 1) Is there a relation between antipsychotic treatment and MS prevalence? 2) Which antipsychotic users have higher MS prevalence? 3) Do patients on antipsychotic polytherapy have higher rates of MS than patients on antipsychotic monotherapy? 4) Which metabolic parameters are considerably disturbed on which antipsychotic users?


METHODS
242 Patients with schizophrenia, schizoaffective disorder and bipolar disorder without any other psychiatric comorbidity according to DSM-IV and using the same antipsychotic(s) and/or mood stabilizers at least for the last 6 months included to the final assessment.


RESULTS
The sample was divided into 7 drug groups. The MS prevalence was highest in the combined antipsychotic (AA) group (48.1%) according to ATP III criteria. According to IDF criteria clozapine (C) group had the highest MS prevalence (74%).


CONCLUSIONS
When metabolic parameters evaluated overall, metabolic risk with antipsychotics is found to be highest in clozapine group, followed by combined AP group. Olanzapine and risperidone have intermediate risk while zuclopentixole has lowest.
Haydarpas¸a Numune Training and Research Hospital, Istanbul, Turkey. cemcerit@yahoo.com
Cem
C
Cerit
Meltem
M
Vural
S Ükriye
SÜ
Bos Gelmez
Eylem
E
Ozten
Ahmet Tamer
AT
Aker
Mustafa
M
Yıldız
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology; D016009:Chi-Square Distribution; D003006:Clopenthixol / Q000009:adverse effects; D003024:Clozapine / Q000009:adverse effects; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D000077152:Olanzapine; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D014421:Turkey / Q000453:epidemiology; D055815:Young Adult
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003006:Clopenthixol; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine